Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Interventional × Palovarotene × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Osteochondroma 1 Exostoses, Multiple Hereditary 1

Interventions

pembrolizumab 885 Carboplatin 842 Paclitaxel 827 Gemcitabine 688 Cisplatin 666 Docetaxel 614 Bevacizumab 542 Pemetrexed 430 Nivolumab 419 Cyclophosphamide 416 Capecitabine 402 Fluorouracil 355 Dexamethasone 343 Rituximab 330 Oxaliplatin 300 Injections 293 atezolizumab 263 Trastuzumab 261 Leucovorin 245 Cetuximab 241 Irinotecan 230 Prednisone 223 130-nm albumin-bound paclitaxel 222 Doxorubicin 216 Ipilimumab 192 Lenalidomide 191 fludarabine 186 Fulvestrant 186 durvalumab 179 Erlotinib Hydrochloride 169

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03442985 2022-08-01

MO-Ped

Ipsen

Phase 2 Terminated

193 enrolled 20 charts

Exostoses, Multiple Hereditary, Osteochondroma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡